Beijing Xuansheng Pharmaceutical

Beijing Xuansheng Pharmaceutical is a Chinese pharmaceutical company specializing in the manufacturing of chemical drug preparations and the provision of CDMO services. Originally established in 2021 as a subsidiary of Sihuan Pharmaceutical Holdings Group, the company was divested in 2022 to Tibet Jiafeng Venture Capital for approximately RMB 118 million. The company operates a manufacturing facility in Beijing's Tongzhou District and holds licenses for drug production, wholesale, and entrusted manufacturing. Its primary commercial product is Roxatidine acetate hydrochloride, an H2 receptor antagonist used to treat various digestive system conditions, including peptic ulcers and gastritis. Beijing Xuansheng is recognized as a national high-tech enterprise and a Specialized and Sophisticated small and medium-sized enterprise in Beijing.